Nurix Therapeutics, Inc. NRIX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s change in accrued liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported change in accrued liabilities of $4.12M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s change in accrued liabilities decreased by 40.6% year-over-year, from $6.94M to $4.12M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s change in accrued liabilities?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s change in accrued liabilities has grown at a 29.2% compound annual growth rate (CAGR), from $6.22M to $17.31M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.